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Abstract
Cirrhotic cardiomyopathy is the term used to describe a constellation of features indicative of
abnormal heart structure and function in patients with cirrhosis. These include systolic and diastolic
dysfunction, electrophysiological changes, and macroscopic and microscopic structural changes.
The prevalence of cirrhotic cardiomyopathy remains unknown at present, mostly because the
disease is generally latent and shows itself when the patient is subjected to stress such as exercise,
drugs, hemorrhage and surgery. The main clinical features of cirrhotic cardiomyopathy include
baseline increased cardiac output, attenuated systolic contraction or diastolic relaxation in
response to physiologic, pharmacologic and surgical stress, and electrical conductance
abnormalities (prolonged QT interval). In the majority of cases, diastolic dysfunction precedes
systolic dysfunction, which tends to manifest only under conditions of stress. Generally, cirrhotic
cardiomyopathy with overt severe heart failure is rare. Major stresses on the cardiovascular system
such as liver transplantation, infections and insertion of transjugular intrahepatic portosystemic
stent-shunts (TIPS) can unmask the presence of cirrhotic cardiomyopathy and thereby convert
latent to overt heart failure. Cirrhotic cardiomyopathy may also contribute to the pathogenesis of
hepatorenal syndrome. Pathogenic mechanisms of cirrhotic cardiomyopathy are multiple and
include abnormal membrane biophysical characteristics, impaired β-adrenergic receptor signal
transduction and increased activity of negative-inotropic pathways mediated by cGMP. Diagnosis
and differential diagnosis require a careful assessment of patient history probing for excessive
alcohol, physical examination for signs of hypertension such as retinal vascular changes, and
appropriate diagnostic tests such as exercise stress electrocardiography, nuclear heart scans and
coronary angiography. Current management recommendations include empirical, nonspecific and
mainly supportive measures. The exact prognosis remains unclear. The extent of cirrhotic
cardiomyopathy generally correlates to the degree of liver insufficiency. Reversibility is possible
(either pharmacological or after liver transplantation), but further studies are needed.
Definition and diagnostic criteria
In cirrhosis, cardiac output increases whereas systemic
vascular resistance and arterial pressure decrease [1,2].
Despite the increased basal cardiac output, cardiac
response to physiologic or pharmacologic stimuli is
known to be subnormal [3-5], a phenomenon called "cir-
rhotic cardiomyopathy" [6,7]. When first described more
than 3 decades ago in cirrhotic patients, cardiac dysfunc-
tion was presumed to result from alcoholic cardiotoxicity,
specifically a latent alcoholic cardiomyopathy [8-10].
Published: 27 March 2007
Orphanet Journal of Rare Diseases 2007, 2:15 doi:10.1186/1750-1172-2-15
Received: 3 January 2007
Accepted: 27 March 2007
This article is available from: http://www.OJRD.com/content/2/1/15
© 2007 Baik et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Orphanet Journal of Rare Diseases 2007, 2:15 http://www.OJRD.com/content/2/1/15
Page 2 of 8
(page number not for citation purposes)
However, during the past 2 decades, it has become clear
that blunted ventricular contractility with stress is also
present in nonalcoholic patients and animal models of
cirrhosis [11-13]. In the 1990s, numerous studies in
patients with nonalcoholic cirrhosis conclusively demon-
strated that depressed ventricular contractile responses to
stimuli are found in all forms of cirrhosis [14-19].
In the absence of consensus definitions, the term "cir-
rhotic cardiomyopathy" is defined at present as: 1) base-
line increased cardiac output but blunted ventricular
response to stimuli, 2) systolic and/or diastolic dysfunc-
tion, 3) absence of overt left ventricular failure at rest, 4)
electrophysiological abnormalities including prolonged
QT interval on electrocardiography and chronotropic
incompetence [7,20-22]. Not all features are required for
the diagnosis; for example, only 30–60% of patients show
a prolonged QT interval.
Epidemiology
Without firm diagnostic criteria, the exact prevalence of
cirrhotic cardiomyopathy remains unknown. Its estima-
tion is a difficult task as the disease is generally latent and
shows itself only when the patient is subjected to stress
such as body position changes, exercise, drugs, hemor-
rhage and surgery. The prevalence of liver cirrhosis is also
difficult to estimate, because many persons with compen-
sated cirrhosis do not exhibit signs or symptoms of the
disease and because noninvasive studies lack sensitivity to
detect cirrhosis at early stages. Moreover there is tremen-
dous geographical variability of cirrhosis worldwide,
depending on the prevalence of the causative factors such
as viral hepatitis B and C, chronic alcoholism, iron over-
load, autoimmune liver disease, etc.
However, we believe that at least one feature of cirrhotic
cardiomyopathy, such as electrocardiographic QT prolon-
gation or diastolic dysfunction, is present in the majority
of patients with cirrhosis who have reached Child-Pugh
stage B or C (representing moderately or severely
advanced liver failure). Moreover, diastolic dysfunction is
probably present in virtually all patients with cirrhotic car-
diomyopathy, and simple echocardiographic indices such
as the E/A ratio may detect diastolic dysfunction even at
rest. Indeed, once cirrhosis has advanced to a moderate
stage, with the accumulation of peripheral edema or
ascites, it appears that some element of diastolic dysfunc-
tion is universally present. For now, tests of diastolic func-
tion by echocardiography or dynamic magnetic
reasonance cardiac imaging may therefore represent the
best available screening test to diagnose the syndrome.
Clinical features
Many aspects of cardiac contraction have been described
to be abnormal in cirrhosis, including histology and struc-
ture, chronotropic, systolic and diastolic function, and
electrophysiological changes.
Functional and structural changes in the cardiac chambers
have been seen in the left heart, rather than the right. Most
studies have found dilatation of the left atrium, and
hypertrophy or dilatation of the left ventricle. The right
atrium and right ventricle generally have normal dimen-
sions and wall thickness in the absence of the uncommon
syndrome of portopulmonary hypertension. Histological
changes of cirrhotic cardiomyopathy include myocardial
fibrosis, subendocardial edema, and nuclear and cytoplas-
mic vacuolation of cardiomyocytes [reviewed in [3,4,7].
However, these conclusions are based on old autopsy
studies in patients with alcoholic cirrhosis, some dating
back almost 8 decades. Whether some of these finding
may simply reflect mild alcoholic cardiotoxicity remains
uncertain.
The chronotropic response to the β-adrenergic agonist iso-
proterenol is attenuated in cirrhotic humans and rats
[13,23]. Cardiac response to physical exercise in cirrhotic
patients is blunted, with subnormal responses in echocar-
diographic ejection fraction and contraction time. Moreo-
ver, both ventricular systolic and diastolic function are
impaired in cirrhosis [3,4,7,22]. Stroke volume and con-
tractile indices are typically normal or even increased at
rest. However, under stressful stimuli such as exercise,
hemorrhage or drug infusions, cirrhotic patients may
show an attenuated systolic function compared to healthy
controls [6,14-19]. For example, normal subjects can tri-
ple their cardiac output with submaximal exercise; cir-
rhotic patients do not exceed a doubling of cardiac output
with exercise [14]. The prevalence and extent of systolic
dysfunction in cirrhotic patients appear to be variable.
In contrast, some element of diastolic dysfunction
appears to be more common. Indeed, some authorities
contend that some degree of diastolic dysfunction is
present in virtually every patient with cirrhosis [16-18,22].
Diastolic dysfunction manifests as a stiff, noncompliant
ventricle, and is often seen in patients with some degree of
left ventricular hypertrophy or dilatation. However, overt
structural changes in the ventricle are not a prerequisite
for diastolic dysfunction. Impaired passive and active fill-
ing of the left ventricle in early and middle-late diastole,
respectively, lead to an inability to adequately increase
stroke volume in response to stimuli. Again, in contrast to
systolic dysfunction, a significant stimulus may not be
required to detect diastolic dysfunction. Echocardiogra-
phy may reveal abnormal diastolic function even at rest
[reviewed in [7,22].
Electrophysiological changes including prolonged repo-
larization and impaired cardiac excitation-contractionOrphanet Journal of Rare Diseases 2007, 2:15 http://www.OJRD.com/content/2/1/15
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coupling have been demonstrated in cirrhotic patients
[24-28]. Repolarization prolongation is manifested by a
prolonged QT interval on the electrocardiogram. Rate-cor-
rected prolongation of the QT (>440 msec) is found in
30–60% of patients with cirrhosis [25-28]. Prolongation
of QT interval can be associated with an increased risk of
certain ventricular arrhythmias, particularly the "torsade
de pointes" type of ventricular tachycardia. However, sud-
den cardiac death is rare in cirrhosis, and torsade de
pointes has only been described in a few patients, all of
whom had other risk factors for this type of ventricular
tachycardia. For example, torsade de pointes has been
reported in patients with variceal bleeding receiving vaso-
pressin [29,30]. Therefore, the clinical significance of QT
prolongation in cirrhosis remains unclear.
In addition to QT prolongation, Henriksen and colleagues
have recently reported that cirrhotic patients show a dis-
persion of the normal interval between the onset of elec-
trical systole (the electrocardiographic QRS complex) and
mechanical systole itself [31]. In other words, this nor-
mally tightly-regulated time interval is subject to wider
variability in cirrhotic patients, either earlier or later than
normal. Again, the clinical relevance of this interesting
observation remains unknown at present.
The exact mechanism leading to these electrophysiologi-
cal changes is unclear. In clinical studies, severity of liver
disease and circulatory dysfunction are related to pro-
longed QT interval. Moreover, these changes disappear
after liver transplantation in most patients [25-28]. Stud-
ies in the cirrhotic rat suggest that functional alterations of
ion channels, particularly one or more types of potassium
channels, in cardiac plasma membranes play a role in ini-
tiating and maintaining cardiac electrophysiological
abnormalities [32,33].
Clinical consequences
Overt heart failure is rare because of the peripheral
vasodilatation characteristic of cirrhosis, in effect
"autotreating" the ventricle by systemic vasodilatation
reducing afterload, and compensatory diminution of
inhibitory influences such as the cardiac muscarinic sys-
tem [3,34]. Although patients may complain of dyspnoea,
reduced exercise capacity, peripheral fluid retention
(dependent oedema) and ascites, these symptoms are
common to both heart failure and advanced cirrhosis. It is
therefore difficult to determine by symptoms if patients
are indeed suffering from symptomatic heart failure. The
only differentiating feature is that dyspnoea in cirrhosis is
usually associated with hydrothorax from ascitic fluid
tracking into the pleural cavity or tense ascites pushing up
against the respiratory diaphragms, and not with pulmo-
nary vascular congestion or frank pulmonary oedema. The
presence of such pulmonary congestion strongly points to
a diagnosis of heart failure, whether due to cirrhotic cardi-
omyopathy or other causes.
Stresses such as liver transplantation, infection and proce-
dures such as insertion of transjugular intrahepatic porto-
systemic stent-shunts (TIPS) can convert latent to overt
heart failure. Indeed, heart failure is responsible for 7–
15% of mortality following liver transplantation [5,35],
and in some series is the third-leading cause of death after
rejection and infection. Numerous studies report acute
left ventricular failure or subtler indices of cardiac dys-
function following liver transplantation, even in patients
with no previous cardiac history or risk factors [36-40].
For example, 12–56% of patients develop clinically overt
or radiographic evidence of pulmonary edema immedi-
ately after transplantation, usually within the first postop-
erative week [22,41].
TIPS are often used to treat recurrent or intractable variceal
bleeding, or ascites. The abrupt shift of a significant por-
tion of the mesenteric venous blood directly into the sys-
temic venous circulation through these portosystemic
shunts dramatically increases the cardiac preload. Several
studies have reported abnormal cardiac response to this
abrupt increase in preload [42-44]. There are also several
case reports and small series of patients with precipitation
of overt left ventricular failure after TIPS insertion [45,46].
Indeed, a recent Spanish-American multicenter study of
TIPS vs large volume paracentesis for treatment of ascites,
reported that 12% of the TIPS group developed heart fail-
ure compared to none in the paracentesis group [46].
Recently, Cazzaniga and colleagues [47] demonstrated
that the E/A ratio, an indicator of diastolic dysfunction,
measured at 4 weeks after TIPS insertion, was the only
independent predictor of survival following this proce-
dure. This suggests that cirrhotic cardiomyopathy is a pri-
mary determinant of survival in cirrhotic patients
undergoing procedures that stress the cardiovascular sys-
tem [48].
Recent studies suggest that cirrhotic cardiomyopathy may
contribute to the pathogenesis of hepatorenal syndrome
(HRS) precipitated by spontaneous bacterial peritonitis
[49-51]. These Spanish studies demonstrated that
amongst patients treated with antibiotics and recovering
from spontaneous bacterial peritonitis, hepatorenal syn-
drome occurred in those whose cardiac output was low at
baseline and failed to increased appropriately after infec-
tion resolution [49]. Later these authors found that 27
patients of a cohort of 66 cirrhotic patients developed
hepatorenal syndrome; cardiac output (lower than in
those who did not develop HRS) and plasma renin activ-
ity were the only factors predictive of HRS occurrence
[50]. The authors suggested that hepatorenal syndromeOrphanet Journal of Rare Diseases 2007, 2:15 http://www.OJRD.com/content/2/1/15
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develops in part due to inadequate cardiac contractility in
the face of marked peripheral vasodilatation.
Etiology and pathogenic mechanisms
There is no direct genetic predisposition to cirrhotic cardi-
omyopathy. The pathogenic mechanisms of cirrhotic car-
diomyopathy include impairment of stimulatory β-
adrenergic receptor signalling pathways, altered cardio-
myocyte plasma membrane physicochemical properties,
and overactivity of negative-inotropic factors such as nitric
oxide, carbon monoxide and endocannabinoid systems
[7,22].
Heart cell contractility is mainly determined by the stimu-
latory β-adrenergic receptor system. When stimulated by
norepinephrine or other catecholamines, the β-adrenergic
receptor-ligand complex couples with G-protein to stimu-
late membrane-bound adenylate cyclase, generating
cAMP which phosphorylates several proteins leading to
intracellular calcium fluxes. The calcium then causes
actin-myosin cross-linking, and thus cellular contraction
[52].
Cardiomyocyte plasma membranes isolated from a rat
model of cirrhosis show multiple defects in the β-adrener-
gic signaling pathway and lipid composition of the mem-
brane bilayer [53,54]. Due to increased cholesterol in the
membrane, the ratio of cholesterol:phospholipids
increases, leading to a biophysical change termed
decreased membrane fluidity [53,54]. Decreased mem-
brane fluidity hampers the conformational movement
ability and thus the function of protein receptors embed-
ded in the membrane, such as calcium channels and β-
adrenergic receptors [52].
Other mechanisms include increased inducible nitric
oxide synthase (iNOS) activity with overproduction of
NO [55-57], and increased heme oxygenase-1 activity that
overproduces carbon monoxide [58]. Both gases inhibit
cardiomyocyte contractility by stimulating soluble guan-
ylate cyclase to produce cGMP. cGMP inhibits contractil-
ity by several mechanisms, mainly by inhibiting calcium
release from the sarcoplasmic reticulum of the cardiomy-
ocyte [59].
Myocardial endocannabinoid production may be
increased in response to stresses such as increased heart
rate and hemodynamic overload [60]; these substances
are known to have a negative inotropic effect in rats [61]
and humans [62]. In that regard, we have recently demon-
strated a pathogenic role of endocannabinoids such as
anandamide in rats with biliary cirrhosis [63]. In isolated
left ventricular papillary muscles from these cirrhotic rats,
increased endocannabinoid signaling via CB1 receptors
contributes to blunted contractile responsiveness to β-
adrenergic stimulation [63].
Diagnostic tests
To date, there is no single diagnostic test that can identify
patients with this condition. The heart produces and
releases peptide hormones such as natriuretic peptides,
and in other conditions, increased release of these hor-
mones indicates cardiac stress or distress. For example,
levels of brain natriuretic peptide, also called B-type natri-
uretic peptide (BNP), are elevated in systolic and diastolic
dysfunction, ventricular hypertrophy and myocardial
ischemia [64,65]. In cirrhotic patients, levels of atrial
natriuretic peptide (ANP) and BNP are elevated due to
increased cardiac release and not because of impaired
hepatic extraction [66,67]. As BNP and its prohormone
proBNP originate from ventricles, it is a more sensitive
marker of ventricular dysfunction, especially in asympto-
matic patients, than ANP which is released from atria.
Increased circulating levels of BNP in asyptomatic cir-
rhotic patients are correlated to QT interval prolongation,
interventricular septal thickness, left ventricular end-
diastolic diameter and impairment of diastolic function
[68,69]. Similarly, cardiac troponin I, a troponin isoform
that is increased in myocardial injury, was reported to be
elevated in patients with predominantly alcoholic cirrho-
sis [70]. At present, the exact role of these markers includ-
ing natriuretic peptides and troponin isoforms in the
noninvasive diagnosis of cirrhotic cardiomyopathy,
remains to be fully clarified.
Some studies have used the measurement of systolic time
intervals as a noninvasive tool to evaluate ventricular con-
tractile performance in cirrhosis. The preejection period
(PEP) to left ventricular ejection time (LVET) ratio is an
important parameter for assessing left ventricular contrac-
tile function. In cardiomyopathy of all types, PEP is pro-
longed and LVET is shortened; thus, PEP/LVET is
increased [71]. However, we believe that failure to stress
the ventricle by a physiological or pharmacological chal-
lenge may not be able to detect the presence of this syn-
drome, because a hallmark of cirrhotic cardiomyopathy is
the subnormal response to stressful stimuli. Some have
advocated using dobutamine stress echocardiography
[41] but a potential theoretical problem with this test is
the downregulation of β-adrenergic receptors in the cir-
rhotic heart. Recently, Torregrosa et al. [36] studied cir-
rhotic patients using echocardiography and stress
radionuclide ventriculography (using physical exercise by
a graded bicycle ergometry in the same position, starting
at zero workload and increasing by 10 W every 1 min).
Some type of standardized exercise protocol appears to be
an effective and safe stress challenge, but still the ideal
screening test for cirrhotic cardiomyopathy remains
unclear at present.Orphanet Journal of Rare Diseases 2007, 2:15 http://www.OJRD.com/content/2/1/15
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Differential diagnosis
Many cardiac conditions resulting in mild or moderate
left ventricular failure may mimic cirrhotic cardiomyopa-
thy. Patients with liver disease may also have concomitant
primary cardiac diseases such as ischemic heart disease,
hypertensive cardiomyopathy or alcoholic cardiotoxicity.
Whether patients with cirrhosis are somehow protected
from developing coronary atherosclerosis remains
unclear. Although this was formerly accepted as dogma,
more recent evidence suggests that cirrhotic patients can
indeed manifest severe coronary artery disease [72]. In
Western countries, alcohol remains a significant cause of
cirrhosis. In that regard, alcohol may precipitate or aggra-
vate heart disease in two ways. First, it is well known that
hypertension becomes more severe or uncontrolled in
alcoholic patients (although if end-stage cirrhosis super-
venes, then arterial pressure often normalizes due to
peripheral vasodilatation). Second, chronic excessive
alcohol is directly cardiotoxic, with alcoholic cardiomy-
opathy a well-described syndrome.
A careful assessment of patient history probing for exces-
sive alcohol, physical examination for signs of hyperten-
sion such as retinal vascular changes, and appropriate
diagnostic tests such as exercise stress electrocardiography,
nuclear heart scans and coronary angiography will help
distinguish these conditions from cirrhotic cardiomyopa-
thy.
Prognosis
The exact prognosis of cirrhotic cardiomyopathy remains
unclear. The weight of evidence indicates that the clinical
features of the syndrome become more prominent or
worsen in parallel with progression of liver failure
[reviewed in [21,22]. In other words, the extent of cir-
rhotic cardiomyopathy generally correlates to the degree
of liver insufficiency. In prognostic terms, as the two con-
ditions are related, mortality and morbidity due to cir-
rhotic cardiomyopathy or its complicating effect on an
intervention such as TIPS insertion, is difficult to pinpoint
as solely due to cirrhotic cardiomyopathy per se. Such an
example is provided by Cazzaniga and colleagues [47],
who found on univariate analysis that the MELD score, an
index of liver failure (Model End Stage Liver Disease), and
diastolic dysfunction as manifested by the E/A ratio were
significantly predictive of death following TIPS insertion.
However, as noted previously, on multivariate analysis,
only the day-28 E/A ratio was an independent predictor,
thus suggesting the interrelationship between the E/A
ratio and the MELD score.
Management
The optimum management of cirrhotic cardiomyopathy
has not been established since there are neither "gold
standard" diagnostic criteria nor specific treatments at
present, recognition of cirrhotic cardiomyopathy depends
on a high level of awareness for the presence of this syn-
drome, particularly in patients with advanced cirrhosis
who undergo significant surgical, pharmacological or
physiological stresses.
If heart failure becomes overt, the usual treatments should
be initiated as for all forms of congestive heart failure,
including bedrest, oxygen, diuretics and careful preload
reduction by drugs [7,73].
Because the β-adrenergic receptor is desensitized in cir-
rhotic cardiomyopathy, inotropic β-agonists such as iso-
proterenol and dobutamine may not benefit patients with
cirrhotic cardiomyopathy. In this regard, previous studies
have demonstrated markedly attenuated vascular
responses to isoproterenol and dobutamine in cirrhotic
patients without overt evidence of heart failure [23,74].
There remains a significant paucity of human or animal
data about specific pharmacological treatments [73,75].
Specific therapies such as β-blockade remain generally
untested in humans or animals with cirrhosis. Henriksen
and colleagues have reported that acute administration of
a single dose of the β-blocker propranolol improves the
prolonged electrocardiographic QT interval in cirrhotic
patients [76], but whether there is also an improvement in
contractile dysfunction with chronic dosing remains
unknown. Cardiac glycoside therapy may not be benefi-
cial; the short-acting glycoside ouabain was ineffective in
patients with severe alcoholic cirrhosis in a study that
dates back 3 decades [10]. Much future research, both
clinical and experimental, is needed in this area. Pozzi
and colleagues [77] recently reported that 6 months of
treatment with the aldosterone antagonist canrenoate par-
tially remodeled the hypertrophied ventricle in cirrhotic
patients, i.e., reduced left ventricular chamber sizes and
wall thickness. However, while diastolic function
improved slightly, these did not reach statistical signifi-
cance. The authors suggested, quite reasonably, that a
more prolonged course of treatment might have allowed
such changes to reach significance. In any case, angi-
otensin/aldsterone inhibitors appear to be a very promis-
ing potential treatment for cirrhotic cardiomyopathy and
need further study.
Orthotopic liver transplantation (OLT) remains the gold
standard of curative therapy in most liver diseases. Even
though the immediate perioperative stresses, particularly
increased arterial pressure (thus increased afterload) asso-
ciated with this operation may unmask latent or overt
myocardial dysfunction [78,79], yet with time, adaptation
to the increased afterload occurs. Hence cardiac function
gradually improves. As mentioned before, the prolonged
QT interval generally normalizes after liver transplanta-Orphanet Journal of Rare Diseases 2007, 2:15 http://www.OJRD.com/content/2/1/15
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tion in most patients. More importantly, Torregrosa1 et al.
[36] in a prospective study reported that OLT caused sig-
nificant improvement of heart function parameters. In
fact, virtually all cardiac alterations detected before trans-
plantation returned to normal: the hyperdynamic state
disappeared, left ventricular wall thickness and left atrial
diameter also decreased. Both systolic and diastolic func-
tion normalized [36]. These results need to be confirmed
in further studies but for now, strongly suggest that liver
transplantation reverses cirrhotic cardiomyopathy [80].
Unresolved questions
Consensus definition criteria, specific diagnostic tests, the
exact prevalence of this syndrome and appropriate man-
agement strategies are all unresolved questions requiring
further study.
Conclusion
Cirrhotic cardiomyopathy is the term used to describe a
constellation of features indicative of abnormal heart
structure and function in patients with cirrhosis. These
include systolic and diastolic dysfunction, electrophysio-
logical changes and macroscopic and microscopic struc-
tural changes. The functional changes often require a
significant stress challenge (exercise or pharmacological)
to become manifest. To date, there is no single diagnostic
test that can identify patients with this condition. Revers-
ibility is possible (either pharmacological or after liver
transplantation), but further studies are needed.
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